Ametov A S, Granovskaia-Tsvetkova A M
Ter Arkh. 1994;66(10):17-9.
The paper presents the results obtained in the treatment of 510 patients with noninsulin-dependent diabetes mellitus (NIDDM). Of them 420 received bucarban, 30 gilemal and 60 adebit. Bucarban and gilemal decreased fasting glycemia and that after the standard meal. The patients were also made less insulin-resistant. Hyperinsulinemia did not respond to the above drugs. Adebit demonstrated hypoglycemic, antihyperinsulinemic, antihyperbetalipoproteinemic and hypocholesterolemic activity. 10% of NIDDM patients developed primary resistance to oral sulfonamide drugs. In intact insulin secretion NIDDM patients were effectively treated both with sulfonamide sugar-reducing drugs and biguanid derivatives.
该论文展示了对510例非胰岛素依赖型糖尿病（NIDDM）患者进行治疗所获得的结果。其中420例接受了布卡班治疗，30例接受了吉列马尔治疗，60例接受了阿德比特治疗。布卡班和吉列马尔降低了空腹血糖以及标准餐后的血糖。患者的胰岛素抵抗也有所减轻。高胰岛素血症对上述药物无反应。阿德比特表现出降血糖、抗高胰岛素血症、抗高β脂蛋白血症和降胆固醇活性。10%的NIDDM患者对口服磺酰胺类药物产生原发性耐药。在胰岛素分泌正常的NIDDM患者中，磺酰胺类降糖药物和双胍衍生物均能有效治疗。
